Krka (KRK) H2 2025 earnings summary

Executive summary

• Revenue increased by 7% year-over-year to €2,041.0 million, with sales volume up 5% to 18.7 billion product units.

• Net profit rose 13% to €403.7 million, and EBITDA grew 7% to €558.7 million compared to 2024.

• All major regions except Overseas Markets saw sales growth, with East Europe leading at €713.4 million (+10%).

• Investments focused on production expansion, technological upgrades, and sustainability initiatives.

Financial highlights

• Gross profit margin improved to 58.0% from 57.3% year-over-year.

• EBIT margin increased to 22.8%, and net profit margin reached 19.8%.

• Return on equity (ROE) rose to 17.5%, and return on assets (ROA) to 13.7%.

• Earnings per share (EPS) climbed 14% to €13.21.

• Market capitalization at year-end was €6.66 billion, up 46%.

Outlook and guidance

• Strategic focus on uninterrupted medicine access, innovative generics for chronic diseases, and value creation.

• Continued investments in production, R&D, and sustainability to support long-term growth.